RE:RE:RE:Value to shareholderswinnerswing wrote: No, I mean value created from Q3 2022 to Q4 2022: the shareholder value creation from the good 2022 year is already included in the Q3 results.
Stocks aren't valued on the basis of a single quarter. Stocks are valued based on the next 10 years into the future, etc. Ignore a given quarter. One quarter in the next ten years is only 2.5% of the stocks value, in a sense.
Q4 is typically the weakest quarter. Individual quarters are lumpy. You need to look at annual results. 2022 was another record year with 10% growth which is consistent with the historic growth rate of the last decade. - "Cash generated from operations of $6,637,000, for the full year 2022 compared to $3,510,000 in 2021." News release
The pipeline continues to advance from approval for the avenanthramide clinical trial, to the fibrosis drug which is before a go/no go clinical trial decision in the summer. The bioavailability results were also exceptional vs. the gold standard.